Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford–AstraZeneca COVID‐19 vaccine: report of three cases from India

Abstract

Case of pemphigoid with immunoglobulin G antibodies to BP180 C-terminal domain and laminin-c1 (p200) developed after pneumococcal vaccination.

Herpes zoster following ChAdOx1 nCoV-19 corona virus vaccine (recombinant): A case report

“…[2] A few reports have started emerging regarding the possible adverse events that followed these vaccines. [5,7,8] Here we report a patient who developed first episode of herpes zoster following Covishield TM vaccine.…”

“…e reported adverse cutaneous reactions include delayed large local reactions, local injection site reactions, urticarial eruptions, morbilliform eruptions, pernio/chilblains, cosmetic filler reactions, flares of herpes zoster and herpes simplex, pityriasis rosea-like reactions, erythema multiforme, Stevens-Johnson syndrome, lymphomatoid drug eruption resembling pityriasis lichenoides et varioliformis acuta, genital fixed drug eruption, annular lichen planus, late-onset atopic dermatitis, cutaneous vasculitis, new-onset bullous pemphigoid, and erythema nodosum. [2][3][4][5] India began the vaccination program against COVID-19 on January 16, 2021. [6] e two vaccines offered were Covishield TM [ChAdOx1 nCoV-19 corona virus vaccine (recombinant) manufactured by Serum Institute of India Pvt Ltd] and Covaxin® (inactivated coronavirus vaccine manufactured by Bharat Biotech Limited).…”

“…[8] e time interval between COVID-19 vaccination and the appearance of herpes zoster as reported in literature ranged 3-20 days which was similar to the finding in our patient. [5,[7][8][9][10][11] Arora et al and van Dam et al have reported that patients who had developed herpes zoster after the first dose of Covaxin® and Pfizer-BioNTech COVID-19 mRNA vaccine respectively, subsequently tolerated the second dose without any adverse events or reactivation of herpes zoster. [8,10] Our patient developed herpes zoster after the second dose of Covishield TM vaccine.…”

A case report of COVID-19-associated erythema nodosum: a classic presentation with a new trigger

“…In the first case, a 25-year-old female in India developed EN 1 week after receiving the Covishield COVID-19 vaccine (Oxford–AstraZeneca), and in the second report, a 27-year-old male developed EN 3 days after the first dose of the MVC-COV1901 COVID-19 vaccine (Medigen Vaccine Biologics Corporation, Taiwan). 14 , 15 COVID-19 vaccine-associated EN appears very rare. In a registry for adverse cutaneous reactions to Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines, no cases of EN were described among the 414 reported reactions.…”

First Case of Erythema Nodosum Associated With Pfizer Vaccine

“…According to a previous study, eight vaccines were found to be related to erythema nodosum, in which they reported the following bacille-Calmette-Guerin vaccine, hepatitis B vaccine, human papillomavirus vaccine, malaria vaccine, rabies vaccine, smallpox vaccine, tetanus, diphtheria, and pertussis vaccine, and typhoid and cholera vaccine [6]. In addition, our literature review revealed three reported cases of COVID-19 vaccine-induce erythema nodosum, in which two of them were AstraZeneca/Oxford vaccines [7,8] and the other one was Medigen vaccine (MVC-COV1901) (Table 1) [9]. Our case is a 22-year-old healthy woman who developed erythema nodosum manifestations shortly after receiving the Pfizer vaccine with no past medical history and normal laboratory and chest radiograph which suggests that erythema nodosum was related only to the Pfizer vaccine.…”